Identification of novel chromenone derivatives as interleukin-5 inhibitors

被引:18
作者
Venkateswararao, Eeda [1 ,2 ]
Kim, Min-Seok [1 ,2 ]
Sharma, Vinay K. [1 ,2 ]
Lee, Ki-Cheul [1 ,2 ]
Subramanian, Santhosh [1 ,2 ]
Roh, Eunmiri [3 ]
Kim, Youngsoo [3 ]
Jung, Sang-Hun [1 ,2 ]
机构
[1] Chungnam Natl Univ, Coll Pharm, Taejon 305764, South Korea
[2] Chungnam Natl Univ, Inst Drug Res & Dev, Taejon 305764, South Korea
[3] Chungbuk Natl Univ, Coll Pharm, Cheongju 361763, South Korea
基金
新加坡国家研究基金会;
关键词
Chromenone analogs; Inhibitor; Interleukin-5; Eosinophils; LYMPHOCYTES-T; STRUCTURAL REQUIREMENT; ACTIVATED EOSINOPHILS; SOPHORICOSIDE ANALOGS; ASTHMA; CHALCONES; CYTOKINES; ANTIBODY; MUCOSA; MODEL;
D O I
10.1016/j.ejmech.2012.11.007
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of (E)-5-alkoxy-3-(3-phenyl-3-oxoprop-1-enyl)-4H-chromen-4-ones (4) and (E)-5-alkoxy-3-(3-hydroxy-3-phenylprop-1-enyl)-4H-chromen-4-ones (5) were synthesized and evaluated for their IL-5 inhibitory activity. Propenone analogs 4 possess some of the structurally important characteristics of isoflavone 2 and chalcone 3 previously known as potent IL-5 inhibitor. However, the inhibitory activity of 4 was weak and therefore this structural hybridization appears to be ineffective for the design of IL-5 inhibitor. Meanwhile the potent activity profile of compounds 5 was discovered. This enhanced activity of 5 compared to 4 could be due to the effective location of hydroxyl group of allylic alcohol moiety of 5 in the 3D structure. The electron withdrawing substituents at position 4 of phenyl ring of 5 enhances the activity possibly due to an increase in the strength of hydrogen bonding property of hydroxyl group of allylic alcohol moiety. (C) 2012 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:31 / 38
页数:8
相关论文
共 29 条
[1]  
[Anonymous], SAMTERS IMMUNOLOGIC
[2]   LYMPHOCYTES-T AND ACTIVATED EOSINOPHILS IN AIRWAY MUCOSA IN FATAL ASTHMA AND CYSTIC-FIBROSIS [J].
AZZAWI, M ;
JOHNSTON, PW ;
MAJUMDAR, S ;
KAY, AB ;
JEFFERY, PK .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1992, 145 (06) :1477-1482
[3]   IDENTIFICATION OF ACTIVATED LYMPHOCYTES-T AND EOSINOPHILS IN BRONCHIAL BIOPSIES IN STABLE ATOPIC ASTHMA [J].
AZZAWI, M ;
BRADLEY, B ;
JEFFERY, PK ;
FREW, AJ ;
WARDLAW, AJ ;
KNOWLES, G ;
ASSOUFI, B ;
COLLINS, JV ;
DURHAM, S ;
KAY, AB .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1990, 142 (06) :1407-1413
[4]   IDENTIFICATION OF LYMPHOCYTES-T, MACROPHAGES, AND ACTIVATED EOSINOPHILS IN THE BRONCHIAL-MUCOSA IN INTRINSIC ASTHMA - RELATIONSHIP TO SYMPTOMS AND BRONCHIAL RESPONSIVENESS [J].
BENTLEY, AM ;
MENZ, G ;
STORZ, C ;
ROBINSON, DS ;
BRADLEY, B ;
JEFFERY, PK ;
DURHAM, SR ;
KAY, AB .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1992, 146 (02) :500-506
[5]   VALIDATION OF THE GENERAL-PURPOSE TRIPOS 5.2 FORCE-FIELD [J].
CLARK, M ;
CRAMER, RD ;
VANOPDENBOSCH, N .
JOURNAL OF COMPUTATIONAL CHEMISTRY, 1989, 10 (08) :982-1012
[6]   RECOMBINANT HUMAN INTERLEUKIN-5 IS AN EOSINOPHIL DIFFERENTIATION FACTOR BUT HAS NO ACTIVITY IN STANDARD HUMAN B-CELL GROWTH-FACTOR ASSAYS [J].
CLUTTERBUCK, E ;
SHIELDS, JG ;
GORDON, J ;
SMITH, SH ;
BOYD, A ;
CALLARD, RE ;
CAMPBELL, HD ;
YOUNG, IG ;
SANDERSON, CJ .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1987, 17 (12) :1743-1750
[7]  
CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504
[8]  
CLUTTERBUCK EJ, 1990, BLOOD, V75, P1774
[9]   COVALENT MODIFICATION OF THE INTERLEUKIN-5 RECEPTOR BY ISOTHIAZOLONES LEADS TO INHIBITION OF THE BINDING OF INTERLEUKIN-5 [J].
DEVOS, R ;
GUISEZ, Y ;
PLAETINCK, G ;
CORNELIS, S ;
TAVERNIER, J ;
VANDERHEYDEN, J ;
FOLEY, LH ;
SCHEFFLER, JE .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1994, 225 (02) :635-640
[10]  
GLEICH GJ, 1993, AGENT ACTION SUPPL, V43, P223